Labcorp 2025 Third Quarter Results and Guidance

These sources provide a comprehensive overview of Labcorp's financial performance and strategic initiatives as presented during their third-quarter 2025 earnings conference call and accompanying documents. The materials reveal that the company achieved strong revenue growth and margin improvement, leading to double-digit adjusted EPS growth, driven largely by momentum in their Diagnostics Laboratories and Central Laboratory businesses. Strategically, Labcorp is focused on acquisitions and partnerships with health systems to expand its market presence and is continually investing in advanced specialty testing (such as oncology and neurology) and AI/digital capabilities to improve efficiency and customer experience. Finally, the company updated its full-year 2025 financial guidance, slightly lowering the revenue midpoint due to currency and acquisition timing, while raising the midpoint for adjusted EPS and free cash flow.

There are no comments yet.

Please log in to write the first comment.